Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Thyroid Neoplasms 3Hypothyroidism 3Breast Neoplasms 2Prostatic Neoplasms 1Neoplasms 1Medulloblastoma 1Goiter 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × Triiodothyronine × Clear all
NCT03787303 2022-05-13

B-TREUH

Aultman Health Foundation

Phase 2 Terminated
7 enrolled 14 charts
Breast

Breast Neoplasms

NCT01360177 2016-07-20

Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Stanford University

Phase NA Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡